Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 44Peripheral Blood Stem Cell Transplantation 25fludarabine phosphate 24Doxorubicin 23Etoposide 22Vincristine 21Prednisone 20Whole-Body Irradiation 19Rituximab 18Filgrastim 16Brentuximab Vedotin 15Mycophenolic Acid 14Cyclosporine 14Busulfan 14Methotrexate 12Radiotherapy 11Cytarabine 11Carboplatin 10Melphalan 9Ifosfamide 9Antilymphocyte Serum 9Tacrolimus 8Methylprednisolone 8Gemcitabine 8Bortezomib 8Dexamethasone 7Vorinostat 6Everolimus 6Crizotinib 6romidepsin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Large-Cell, Anaplastic × visilizumab × Clear all
NCT00006009 2013-05-15

Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
DermatologicLymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡